{"id":"W2898490299","doi":"10.1093/annonc/mdy424.065","title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"KU Leuven; Genentech; AstraZeneca; Celgene; Novartis Pharma; Astellas Pharma; Clovis Oncology; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Atezolizumab; Pemetrexed; Oncology; Population; Carboplatin; Docetaxel; Progression-free survival; Adverse effect; Paclitaxel; Clinical endpoint; Chemotherapy; Randomized controlled trial; Cancer; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004277093,0.0002959169,0.001645894,0.0003401526,0.0001038544,0.000007988491,0.000156511,0.0001517289,0.0002246918],"category_scores_gemma":[0.0002118283,0.0001846727,0.0001266855,0.0007606557,0.0002972809,0.0001036525,0.00006434284,0.0001523884,0.000001348086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000824409,"about_ca_system_score_gemma":0.0005509683,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006179543,"about_ca_topic_score_gemma":0.02067811,"domain_scores_codex":[0.9977555,0.000188506,0.000845835,0.0005036711,0.0003764238,0.0003300923],"domain_scores_gemma":[0.9975981,0.0005382469,0.0005706945,0.0006042663,0.0005146927,0.000174022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5976933,0.01785969,0.1825198,0.00007428123,0.008523898,0.0003867766,0.03265039,0.0001345137,0.002106766,0.00001172408,0.0001247179,0.1579142],"study_design_scores_gemma":[0.7423409,0.1344715,0.1049665,0.0003028703,0.003195018,0.00002360446,0.007876649,0.001214265,0.003860804,0.0001312646,0.001200713,0.0004158544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937338,0.0006370107,0.0001058012,0.0008506495,0.00008728645,0.002816217,0.0001293478,0.0000240339,0.001615819],"genre_scores_gemma":[0.9979145,0.0005231538,0.0007717987,0.0001694127,0.00007757251,0.0002629764,0.000102773,0.00003191198,0.0001459244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1574984,"threshold_uncertainty_score":0.997192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03699190091645593,"score_gpt":0.4389857752545097,"score_spread":0.4019938743380537,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}